Aprea Therapeutics Inc APRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
-
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
-
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
-
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
-
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
-
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
-
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
-
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $2.92
- Day Range
- $2.73–2.95
- 52-Week Range
- $2.25–8.85
- Bid/Ask
- $2.60 / $2.78
- Market Cap
- $14.94 Mil
- Volume/Avg
- 9,365 / 8,681
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.aprea.com
Valuation
|
Metric
|
APRE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.58 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
APRE
Financial Strength
|
Metric
|
APRE
|
|---|---|
Quick Ratio | 9.27 |
Current Ratio | 9.55 |
Interest Coverage | — |
Quick Ratio
APRE
Profitability
|
Metric
|
APRE
|
|---|---|
Return on Assets (Normalized) | −44.64% |
Return on Equity (Normalized) | −54.38% |
Return on Invested Capital (Normalized) | −60.02% |
Return on Assets
APRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qxmpfpchb | Xmjx | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hglcbxz | Lvnfcjr | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vchvhtsss | Gcdxp | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wbvgsnvky | Pvmnhc | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Qnwknhvh | Zbqp | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Tkqsfzr | Kpbk | $28.1 Bil | |||
| Moderna Inc
MRNA
| Dwxzdlsv | Gwq | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Wfqqtvzsd | Gnrl | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cqsflzwwm | Gwpsmln | $13.4 Bil | |||
| Incyte Corp
INCY
| Zdtphvkc | Dlrhvx | $12.7 Bil |
United States